Rosuvastatin antilipemic agent Rosuvastatin treat dyslipidemia

Rosuvastatin inhibits the enzyme hydroxymethylglutaryl-CoA reductase in the liver, which reduces cholesterol synthesis and lowers serum cholesterol and triglyceride levels. Moreover, Rosuvastatin increases the liver's uptake and breakdown of low-density lipoprotein cholesterol (LDL-C), while also raising the levels of high-density lipoprotein cholesterol (HDL-C). In addition to its lipid-lowering effects, Rosuvastatin has been shown to possess anti-atherosclerotic, anti-inflammatory, antioxidant, plaque stabilizing, and improved endothelial function properties.

Rosuvastatin is produced via fermentation of Aspergillus terreus or through chemical synthesis. Once ingested, it is extensively metabolized in the liver and converted into various metabolites, including active metabolites that inhibit HMG-CoA reductase. The drug and its metabolites are primarily excreted in feces, with a small amount excreted in urine.